Talk:Sofosbuvir
| This is the talk page for discussing improvements to the Sofosbuvir article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
Archives: 1Auto-archiving period: 200 days  |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Sofosbuvir.
|
Side effects
I don't think that long discussion of side effects belongs in the introduction (if anywhere). That's especially true of generalized, non-specific symptoms like tiredness, headache, and difficulty sleeping.
WP:MEDMOS "a long list of side effects is largely useless without some idea of which are common or serious."
We shouldn't just copy the FDA package insert (especially since Wikipedia isn't written for the practice of medicine). I would just mention those side effects that are common, significant and treatment-limiting. --Nbauman (talk) 00:49, 20 March 2017 (UTC)
- The lead currently says "Common side effects include feeling tired, headache, nausea, and trouble sleeping.[1] Side effects are generally more common in interferon-containing regimens.[2]: 7 Sofosbuvir may reactivate hepatitis B in those who have been previously infected.[3]" How is that "long"? And common = between 1 and 10% of people experience them - these are the most common side effects.
References
- ^ "Sofosbuvir". The American Society of Health-System Pharmacists. Retrieved Nov 30, 2016.
- ^ "Sofosbuvir label" (PDF). FDA. August 2015.
- ^ "Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating". FDA. 4 October 2016. Retrieved 6 October 2016.
-- Jytdog (talk) 08:29, 20 March 2017 (UTC)
with or without ribavirin and PEG
My friendly neighborhood hepatologist tells me that use " only recommended with some combination of ribavirin, peginterferon-alfa.. . is no longer true (the RIBA and PEG, not the combination with other DAA agents. See 2020 European Association for the Study of Liver Diseases guidelines"
Pawlotsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology [Internet]. 2020 Nov 1 [cited 2021 Apr 26];73(5):1170–218. Available from: https://www.sciencedirect.com/science/article/pii/S0168827820305481 JuanTamad (talk) 06:42, 31 May 2021 (UTC)
- Could you clarify? Do you mean that the combinations with ribavirin or peginterferon are no longer recommended? --ἀνυπόδητος (talk) 06:37, 4 June 2021 (UTC)
- that’s right. The direct-acting agents can work without riba and peg, which are responsible for most side effects. That’s my understanding but check the EASL recommendation. JuanTamad (talk) 06:53, 4 June 2021 (UTC)
- Thanks! I'll look into it when time allows. --ἀνυπόδητος (talk) 11:58, 7 June 2021 (UTC)
- The European and US labels still say it's approved in combination with ribavirine. I's rather leave this to someone more knowledgeable about this subject. --ἀνυπόδητος (talk) 13:34, 24 June 2021 (UTC)
- that’s right. The direct-acting agents can work without riba and peg, which are responsible for most side effects. That’s my understanding but check the EASL recommendation. JuanTamad (talk) 06:53, 4 June 2021 (UTC)